MBIO Mustang Bio Inc: Operating Profitability

Mustang Bio Inc (MBIO) - corporate logo

Mustang Bio, Inc. (MBIO) focuses on developing CAR-T therapies, attracting leading geneticists through stock option programs. The operating profitability history illustrates the market response, where 0.00 captures the current state of the parameter. Its own manufacturing facility in the US guarantees control over biologics, yet a capital shortage is forcing the company to divest assets, eliminating the possibility of current product pricing.

MBIO: Mustang Bio, Inc. Operating Sales Margin 07/04/2022 - 11/19/2026

Analytical breakdowns for Mustang Bio, Inc.

- share price and consensus valuation forecast:
- company stock capitalization data:
Summary company analysis:Mustang Bio Corp, MBIO
Core merchandise of Mustang Bio

Operating margin measures cost management efficiency, reflecting the share of profit from core operations in total revenue before taxes and interest obligations. By analyzing the marginal income from primary activities, an investor will see how geopolitical isolation and the disruption of biomaterial logistics limit the clinical trials of Mustang Bio, Inc. (MBIO), directly reducing profitability and creating risks for capital.

Competitor analysis

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Margin RGNX|Operating Profitability SLDB (Solid Biosciences)|Ocugen Corp - Operating Sales Margin|PACB: Return on Sales by Operating Profit|benitec.com - Operating Margin|DSGN - Operating Margin|RCKT: Operating Margin|FDMT (4D Molecular Therapeutics Inc) - Operating Profitability|Operating Sales Margin LXEO|Operating Profitability KRRO|Operating Margin EDIT|SLN - Operating Return on Sales|Operating Margin PRQR (ProQR)|CDXS - Operating Sales Margin|Sangamo Therapeutics Inc. - Operating Margin|NAUT - Operating Margin|MGX: Operating Margin|Operating Sales Margin Precision BioSciences, Inc.|GBIO (Generation Bio) - Operating Margin|Boundless Bio Inc. (BOLD) - Profitability of Operations|Operating Sales Margin XCUR (exicuretx.com)|Imunon Inc - Return on Sales by Operating Profit|Operating Margin PHIO (Phio Pharmaceuticals Corp)|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability